Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... about being disappointed by not being able to visit a ... view of their services after an executive scheduled a meeting with ... I would get. Several calls came in within 15 minutes of ... a lot to say about watching claims made within the data ...
... - In 2000, so-called cleantech investments made up only one ... By late 2006, that slice of the venture capital pie ... markets are warming to technologies that produce alternative fuels, keep ... ,And while some environmentalists or policymakers may prefer to pick ...
... has completed its $185 million sale of ... Ind. , ,The sale, subject to federal and state regulatory ... complete. , ,Journal Communications said it will use the proceeds ... taxes and transaction expenses - to reduce debt. , ...
Cached Biology Technology:Data centers: Buyers beware of over-hyped facilities 2Data centers: Buyers beware of over-hyped facilities 3Data centers: Buyers beware of over-hyped facilities 4Bio-energy and cleantech grab attention of investors 2Bio-energy and cleantech grab attention of investors 3Bio-energy and cleantech grab attention of investors 4
(Date:4/20/2014)... cells demonstrate a bizarre property never before seen ... today from scientists at the University of Cambridge. The ... may have application as wide-ranging as soundproofing, super-absorbent sponges ... For example, if one pulls on an elastic band, ... also true: squeeze a material and it will expand ...
(Date:4/20/2014)... April 20, 2014 -- Using corn crop residue to ... can generate more greenhouse gases than gasoline, according to ... Climate Change . , The findings by a University ... corn residue can be used to meet federal mandates ... emissions. , Corn stover -- the stalks, leaves and ...
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Ancient DNA offers clues to how barnyard chickens came to be 2
... gene influences taste sensitivity of children and adults, accounting ... report a team of researchers from the Monell Chemical ... also contribute to taste preferences, at times overriding the ... explain why some children are more attracted to sweet-tasting ...
... appears to play a key role in the development of ... a disease that affects about one million people in the ... findings, which they say could lead to new drug interventions ... of the American Chemical Society, the world's largest scientific society. ...
... density appears to recover in adolescent females once they ... according to a study funded by the National Institute ... Institutes of Health. , Previous studies had shown that ... Depo-Provera, experience a loss of bone mineral density during ...
Cached Biology News:Children's taste sensitivity and food choices influenced by taste gene 2Children's taste sensitivity and food choices influenced by taste gene 3Towards precise classification of cancers based on robust gene functional expression profiles 2Towards precise classification of cancers based on robust gene functional expression profiles 3Bone Density Recovers After Teens Stop Injected Contraceptive 2Bone Density Recovers After Teens Stop Injected Contraceptive 3
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Limit of detection: <5 pg/ml...
Biology Products: